********* webinar 11 June 2021, page-26

Ok same page. If you read my first post shortly after the presentation I was kindly critical of his presentation,

My point about product placement was that putting BRN immediately after both RACE and IMU was aimed at capturing the institutional investors in the biomedicine space by alerting them to the fact that BRN has a device for early noninvasive diagnosis of these types of cancer.

Brainchip is as Peter can der Made stated on a mission to raise institutional interest.

Those who understood the RACE and IMU presentations were primed to remember that currently and going forward early detection dramatically improves survival rates and that there is big money in early detection.

All perfectly reasonable conduct from a business development perspective but underlying all of these three presentations are real people dying.

All a bit unpleasant how it has to be done.

My opinion only DYOR
FF

AKIDA Ballista